T. Rowe Price Investment Management Inc. Has $75.40 Million Stake in Immatics (NASDAQ:IMTX)

T. Rowe Price Investment Management Inc. grew its holdings in Immatics (NASDAQ:IMTX - Free Report) by 43.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,604,777 shares of the company's stock after acquiring an additional 3,225,141 shares during the quarter. T. Rowe Price Investment Management Inc. owned 8.88% of Immatics worth $75,400,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IMTX. Wellington Management Group LLP boosted its position in shares of Immatics by 7.6% in the fourth quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company's stock valued at $74,071,000 after acquiring an additional 736,709 shares during the period. Schroder Investment Management Group lifted its position in Immatics by 52.6% during the fourth quarter. Schroder Investment Management Group now owns 427,994 shares of the company's stock worth $2,953,000 after purchasing an additional 147,547 shares during the period. abrdn plc lifted its position in Immatics by 49.2% during the fourth quarter. abrdn plc now owns 347,379 shares of the company's stock worth $2,470,000 after purchasing an additional 114,479 shares during the period. Platinum Investment Management Ltd. lifted its position in Immatics by 53.1% during the fourth quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company's stock worth $2,216,000 after purchasing an additional 108,108 shares during the period. Finally, Wasatch Advisors LP lifted its position in Immatics by 9.7% during the fourth quarter. Wasatch Advisors LP now owns 957,052 shares of the company's stock worth $6,805,000 after purchasing an additional 84,541 shares during the period. Institutional investors own 64.41% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Immatics has an average rating of "Buy" and a consensus target price of $16.67.

Immatics Trading Up 0.2 %

NASDAQ:IMTX traded up $0.01 on Thursday, hitting $5.01. The company had a trading volume of 102,154 shares, compared to its average volume of 651,323. The firm has a 50 day moving average of $4.44 and a two-hundred day moving average of $6.27. The stock has a market capitalization of $608.97 million, a price-to-earnings ratio of -7.57 and a beta of 0.85. Immatics has a 52 week low of $3.30 and a 52 week high of $13.77.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.51. The firm had revenue of $15.67 million for the quarter, compared to analysts' expectations of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. As a group, equities analysts forecast that Immatics will post -0.72 EPS for the current year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.